Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to natalizumab versus interferon beta-1a or glatiramer acetate in active relapsing-remitting multiple sclerosis
NL-OMON34882Phase 3Withdrawn
- Sponsor
- Biogen
- Start
- Jun 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in multiple sclerosis (MS) comparing Natalizumab, Interferon beta-1a and Glatiramer acetate (3 arms). Primary endpoint: Annualized relapse rate. Planned start Jun 2010; status: withdrawn.
02
Drugs
natalizumabinterferon beta-1aglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON34882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34882.